Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
The drugmaker has successfully moved experimental drugs into position to win approval by regulators. But only once in the
last four years has a new drug actually made it to market—the industry’s equivalent of getting
across the goal line.
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Eli Lilly and Co. has experienced a string of setbacks in recent years. Is it still a good place to work?
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
Drugmaker Eli Lilly and Co. spent nearly $3.6 million in the second quarter lobbying the federal government on health care
reform and trademark issues, among other topics, according to a recent disclosure form.
The price of Eli Lilly and Co.’s stock veered lower this morning after a Goldman Sachs analyst downgraded her rating from
neutral to sell.
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.
Safeco is leaving a five-building complex on North Meridian Street, and Eli Lilly and Co. has offered for lease its entire
four-building Faris campus.
The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add
315 jobs at its Greenfield Laboratories.
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.
Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force,
with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though
it’s far from the lucrative payoff they’d once imagined.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
